Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.

about

Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.

Item

http://www.wikidata.org/entity/Q40454267

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Anthropometrics and prognosis ...... icentre study of 653 patients.

@en

type

Item

label

Anthropometrics and prognosis ...... icentre study of 653 patients.

@en

prefLabel

Anthropometrics and prognosis ...... icentre study of 653 patients.

@en

P1476

Anthropometrics and prognosis ...... icentre study of 653 patients.

@en

P2093

Christian Brieghel

http://www.w3.org/2001/XMLSchema#string

Eric Bekric

http://www.w3.org/2001/XMLSchema#string

Kristina Buchardi Nielsen

http://www.w3.org/2001/XMLSchema#string

Peter Svenssen Munksgaard

http://www.w3.org/2001/XMLSchema#string

Peter de Nully Brown

http://www.w3.org/2001/XMLSchema#string

P2860

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

The Danish National Lymphoma Registry: Coverage and Data Quality

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.

Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified.

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

P304

355-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12835

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Martin Bøgsted

Tarec Christoffer El-Galaly

Hans Erik Johnsen

Karen Dybkaer

Mette Dahl Bendtsen

Marianne T Severinsen

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27893172

http://www.w3.org/2001/XMLSchema#string

P921

anthropometry

multicenter trial